CLAIMS

1. An isolated polypeptide encoded by the nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 2-11 or a nucleic acid complementary to a sequence selected from the group consisting of SEQ ID NOs: 2-11.
2. An isolated polypeptide encoded by a variant of any of one of SEQ ID NOs: 2-11 or a variant of a nucleic acid complementary to a sequence selected from the group consisting of SEQ ID NOs; 2-11, wherein said variant has at least about 80% sequence identity to SEQ ID NOs: 2-11 or a nucleic acid complementary to the sequence of any of SEQ ID NOs:-2-11.
3. The isolated polypeptide of claim 2, wherein the variant ranges from about 99.5% to about 85% identity to any of SEQ ID NOs: 2-11or a sequence complementary to any of SEQ ID NOs:-2-11.
4. An immunogenic composition comprising the Tilapia Lake Virus polypeptide, according to claim 1.
5. An immunogenic composition comprising the Tilapia Lake Virus polypeptide, according to claim 2.
6. An immunogenic composition comprising the Tilapia Lake Virus polypeptide, according to claim 3.
7. An immunogenic composition comprising a killed virus and/or attenuated virus comprising a Tilapia Lake Virus polypeptide, wherein the polypeptide is encoded by a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 2-11 or a nucleic acid complementary to a sequence selected from the group consisting of SEQ ID NOs: 2-11.
8. The immunogenic composition of claim 7 further comprising at least one excipient, additive or adjuvant.
9. An immunogenic composition of claim 5 for use in inducing an immune response in an animal.
10. An immunogenic composition of claim 5 for use in inhibiting or reducing a Tilapia Lake Viral infection in an animal.
11. The composition for use according to claim 9, wherein the immunogenic composition is to be administered orally, by immersion or by injection.

12. A method for determining whether or not a sample contains Tilapia Lake Virus or has been infected by Tilapia Lake Virus, the method comprising:

    a) contacting a biological sample with an antibody that specifically binds to a polypeptide encoded by the nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 2-11, fragments and variants thereof; and

    b) determining whether or not the antibody binds to an antigen in the biological sample, wherein binding indicates that the biological sample contains Tilapia Lake Virus.

13. An immunogenic composition of claim 6 for use in inducing an immune response in an animal.
14. An immunogenic composition of claim 6 for use in inhibiting or reducing a Tilapia Lake Viral infection in an animal.
15. The composition for use according to claim 14, wherein the immunogenic composition is to be administered orally, by immersion or by injection.
16. An immunogenic composition of claim 4 for use in inducing an immune response in an animal.
17. An immunogenic composition of claim 4 for use in inhibiting or reducing a Tilapia Lake Viral infection in an animal.
18. The composition for use according to claim 18, wherein the immunogenic composition is to be administered orally, by immersion or by injection.
19. The immunogenic composition of any one of claims 4 to 6, further comprising at least one excipient, additive or adjuvant chosen from the group consisting of oil, feed, gelatin and other additives or adjuvants that enhance and/or prolong the immune response.
20. The immunogenic composition of claim 19, wherein the at least one excipient, additive, or adjuvant is chosen from the group consisting of oil, feed, and gelatin.